Financial Performance - The company's operating revenue for Q1 2025 was ¥920,204,017.65, a decrease of 19.91% compared to ¥1,148,946,834.25 in the same period last year[5] - Net profit attributable to shareholders was ¥143,544,555.30, down 11.86% from ¥162,863,217.96 year-on-year[5] - Basic and diluted earnings per share were both ¥0.32, reflecting an 11.11% decline from ¥0.36 in the same period last year[6] - Total revenue for Q1 2025 was RMB 920,204,017.65, a decrease of 19.93% compared to RMB 1,148,946,834.25 in Q1 2024[20] - Operating profit for Q1 2025 was ¥124,230,926.58, down from ¥142,970,237.88 in Q1 2024, reflecting a decline of 13.1%[34] - Net profit for Q1 2025 was ¥116,141,414.65, compared to ¥129,419,933.08 in Q1 2024, representing a decrease of 10.2%[34] - The total comprehensive income for the period was CNY 145,066,811.69, compared to CNY 163,945,932.09, reflecting a decrease of about 11.5%[22] Cash Flow - The net cash flow from operating activities decreased by 76.53%, amounting to ¥57,513,417.42 compared to ¥245,031,646.54 in the previous year[5] - The net cash flow from operating activities was CNY 57,513,417.42, significantly lower than CNY 245,031,646.54 in the same period last year, reflecting a decline of approximately 76.6%[24] - In Q1 2025, the net cash flow from operating activities was ¥20,755,809.71, a significant decrease of 88.6% compared to ¥182,959,351.08 in Q1 2024[36] - The net cash flow from investing activities was negative at CNY -348,187,435.26, compared to CNY -221,438,840.30 in the same period last year, indicating a worsening of approximately 57.3%[26] - The net cash flow from investment activities was -¥344,803,552.58 in Q1 2025, worsening from -¥234,003,505.84 in Q1 2024[37] - The net increase in cash and cash equivalents for Q1 2025 was -¥375,710,743.19, compared to -¥59,155,775.30 in Q1 2024, indicating a worsening liquidity position[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,597,520,023.49, a slight increase of 0.58% from ¥7,553,814,810.05 at the end of the previous year[6] - Current assets as of March 31, 2025, totaled RMB 4,887,371,204.72, slightly down from RMB 4,961,714,730.43 as of December 31, 2024[16] - Total liabilities decreased to RMB 1,461,232,590.39 from RMB 1,566,866,075.86, a decline of 6.73%[18] - Total current assets decreased slightly from ¥4,375,673,177.87 as of December 31, 2024, to ¥4,261,967,480.90 as of March 31, 2025[29] - Total non-current assets increased from ¥2,404,364,267.86 as of December 31, 2024, to ¥2,522,646,806.16 as of March 31, 2025[29] - Total liabilities decreased from ¥1,403,564,367.43 as of December 31, 2024, to ¥1,291,999,794.11 as of March 31, 2025[30] - The company's total equity increased from ¥5,376,473,078.30 as of December 31, 2024, to ¥5,492,614,492.95 as of March 31, 2025[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,375[11] - The largest shareholder, Chenxin Technology Group Co., Ltd., held 26.26% of the shares, totaling 118,891,080 shares[12] - The company reported no significant changes in major shareholders or their participation in financing activities[13] Investment and Expenses - The company's investment income increased by 154.79%, indicating a significant rise in investment returns during the reporting period[9] - Research and development expenses were CNY 73,643,696.38, down from CNY 100,074,377.52, showing a reduction of about 26.4% year-over-year[21] - Research and development expenses for Q1 2025 were ¥70,701,621.24, down from ¥81,709,281.41 in Q1 2024, a decrease of 13.5%[34] - The company's total operating costs were CNY 741,656,866.42, a decrease from CNY 954,816,641.05, representing a reduction of about 22.3%[21] - The company reported a financial income of ¥6,272,927.25 in Q1 2025, compared to ¥10,438,291.41 in Q1 2024, indicating a decline of 40.5%[34]
辰欣药业(603367) - 2025 Q1 - 季度财报